TRCT
BIIB icon

Tower Research Capital (TRC)’s Biogen BIIB Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Sell
2,159
-1,672
-44% -$308K 0.01% 1092
2025
Q4 		$674K Buy
3,831
+356
+10% +$58.2K 0.02% 663
2025
Q3 		$487K Buy
3,475
+561
+19% +$75.8K 0.01% 880
2025
Q2 		$366K Sell
2,914
-5,311
-65% -$662K 0.01% 1244
2025
Q1 		$2.02M Sell
8,225
-1,894
-19% -$271K 0.06% 281
2024
Q4 		$1.55M Buy
10,119
+4,163
+70% +$702K 0.03% 440
2024
Q3 		$1.15M Sell
5,956
-9,512
-61% -$1.99M 0.03% 481
2024
Q2 		$3.59M Buy
15,468
+4,062
+36% +$883K 0.06% 271
2024
Q1 		$2.46M Sell
11,406
-15,983
-58% -$3.74M 0.06% 231
2023
Q4 		$7.09M Buy
27,389
+17,302
+172% +$4.25M 0.09% 180
2023
Q3 		$2.59M Buy
10,087
+6,561
+186% +$1.75M 0.08% 241
2023
Q2 		$1M Buy
3,526
+282
+9% +$83.9K 0.03% 515
2023
Q1 		$901K Sell
3,244
-1,764
-35% -$488K 0.03% 507
2022
Q4 		$1.39M Sell
5,008
-30,785
-86% -$8.69M 0.06% 266
2022
Q3 		$9.56M Buy
35,793
+4,001
+13% +$850K 0.16% 118
2022
Q2 		$6.48M Sell
31,792
-15,292
-32% -$3.13M 0.15% 111
2022
Q1 		$9.92M Buy
47,084
+34,339
+269% +$7.47M 0.09% 187
2021
Q4 		$3.06M Buy
12,745
+1,745
+16% +$449K 0.05% 301
2021
Q3 		$3.11M Buy
11,000
+4,263
+63% +$1.4M 0.08% 176
2021
Q2 		$2.33M Sell
6,737
-13,174
-66% -$3.99M 0.06% 266
2021
Q1 		$5.57M Buy
19,911
+13,068
+191% +$3.52M 0.09% 191
2020
Q4 		$1.68M Sell
6,843
-612
-8% -$158K 0.05% 278
2020
Q3 		$2.12M Buy
7,455
+2,831
+61% +$790K 0.02% 358
2020
Q2 		$1.24M Buy
4,624
+4,552
+6,322% +$1.37M 0.05% 398
2020
Q1 		$23K Sell
72
-107
-60% -$32.5K ﹤0.01% 1637
2019
Q4 		$53K Sell
179
-2,122
-92% -$589K ﹤0.01% 1301
2019
Q3 		$536K Sell
2,301
-4,856
-68% -$1.13M 0.04% 547
2019
Q2 		$1.67M Buy
7,157
+2,803
+64% +$647K 0.11% 135
2019
Q1 		$1.03M Buy
4,354
+3,773
+649% +$1.19M 0.06% 271
2018
Q4 		$175K Sell
581
-6,732
-92% -$2.15M 0.01% 737
2018
Q3 		$2.58M Sell
7,313
-7,303
-50% -$2.51M 0.19% 86
2018
Q2 		$4.24M Buy
14,616
+13,459
+1,163% +$3.78M 0.24% 80
2018
Q1 		$317K Sell
1,157
-96
-8% -$29.8K 0.03% 683
2017
Q4 		$399K Sell
1,253
-388
-24% -$124K 0.05% 343
2017
Q3 		$513K Buy
+1,641
New +$486K 0.04% 251
2017
Q1 		– Sell
-382
Closed -$108K – 3071
2016
Q4 		$108K Buy
+382
New +$113K 0.01% 925
2016
Q3 		– Sell
-1,267
Closed -$307K – 3652
2016
Q2 		$307K Buy
1,267
+877
+225% +$231K 0.03% 436
2016
Q1 		$102K Buy
+390
New +$103K 0.02% 496
2015
Q4 		– Sell
-93
Closed -$27K – 4474
2015
Q3 		$27K Buy
93
+18
+24% +$5.94K ﹤0.01% 1480
2015
Q2 		$30K Sell
75
-414
-85% -$166K ﹤0.01% 1761
2015
Q1 		$206K Buy
489
+454
+1,297% +$179K 0.03% 397
2014
Q4 		$12K Sell
35
-4,566
-99% -$1.48M ﹤0.01% 1969
2014
Q3 		$1.52M Buy
4,601
+4,204
+1,059% +$1.39M 0.17% 117
2014
Q2 		$125K Buy
+397
New +$119K 0.02% 786
2014
Q1 		– Sell
-4,128
Closed -$1.15M – 4438
2013
Q4 		$1.15M Sell
4,128
-2,447
-37% -$633K 0.19% 72
2013
Q3 		$1.58M Buy
+6,575
New +$1.47M 0.17% 113

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Tower Research Capital (TRC)'s BIIB Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Biogen (BIIB) stake by 44% in Q1 2026, selling an estimated $308K and leaving 2,159 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #1092.

Tower Research Capital (TRC) first reported a position in BIIB in Q3 2013 and has held it in 46 quarters since. The position peaked at $9.92M in Q1 2022. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Tower Research Capital (TRC) held 2,159 shares of Biogen worth $396K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,672 Biogen shares in Q1 2026, an estimated $308K.
  • Biogen made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1092 holding.
  • Tower Research Capital (TRC) first reported a position in Biogen in Q3 2013 and has held it in 46 quarters since.
  • Tower Research Capital (TRC)'s Biogen position peaked at $9.92M in Q1 2022.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.